Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake

Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)
Overall Status
Not yet recruiting
CT.gov ID
NCT04799301
Collaborator
(none)
60
Enrollment
1
Location
3
Arms
72.8
Anticipated Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background:

Diet is one of the most modifiable behaviors affecting health. But diet assessment measures that are based on self-report can be inaccurate. Researchers want better ways to address the role of diet in chronic disease. They want to see if stable isotopes can be used to better assess what people eat.

Objective:

To see if stable isotopes can help scientists identify things people eat.

Eligibility:

Healthy adults ages 18 to 65

Design:

Participants will be screened with a medical history and physical exam. They will have blood and urine tests. These tests will be repeated during the study.

Participants will stay in the inpatient unit of the NIH in Phoenix, Arizona, for 13 weeks.

For 7 days, participants will eat a diet prepared by the NIH kitchen. They will get balanced meals that are 50% carbohydrates, 20% protein, and 30% fat. Then participants will be randomly placed on one of 3 diets containing different percentages of carbohydrates from soda.

Participants height and weight will be measured. The amount of fat and muscle in their body will be measured by body scans that are similar to x-rays.

Participants will have oral glucose tolerance tests. They will consume a sugar drink and then give blood samples over 3 hours.

Participants will give hair and stool samples.

Participants will complete a diet questionnaire. It assesses their food intake over 24 hours.

Participants will complete behavioral questionnaires and computer performance tests.

Participants will have fat biopsies taken from their stomach and thigh.

Participants will have three 24-hour stays in a metabolic chamber. It is used to measure metabolism.

Condition or DiseaseIntervention/TreatmentPhase
  • Behavioral: Diet with no soda
  • Behavioral: Diet with 50% of carb intake from soda
  • Behavioral: Diet with 20% of carb intake from soda
Phase 1

Detailed Description

This study will be an inpatient study in which highly specific diets will be fed to volunteers for approximately 12 weeks and stable isotopes will be measured in blood and hair. Participants will be randomized to one of three diets: a weight-maintaining diet without soda, a weight maintaining diet with 20% of carbohydrates provided as soda, and a weight maintaining diet with 40% of carbohydrates provided as soda. Ultimately, the goal is to develop biomarkers to be used to validate food intake patterns in outpatient clinical and epidemiological studies. The primary objective of this study is to validate the use of stable isotope biomarkers as representatives of specific dietary intake patterns; changes in the blood and hair carbon stable isotope ratio (13C/12C) will be measured from baseline to 12 weeks. Secondary objectives include evaluation of the effect of the amount of soda on urinary sucrose and fructose excretion, extracellular vesicles levels and content, and gut microbiota, measured from baseline to 12 weeks. Study volunteers will be adult non-diabetic men and women who are in good health.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
Anticipated Study Start Date :
Dec 8, 2021
Anticipated Primary Completion Date :
Jan 1, 2028
Anticipated Study Completion Date :
Jan 1, 2028

Arms and Interventions

ArmIntervention/Treatment
Experimental: Diet with 20% of carb intake from soda

This group will receive a weight-maintaining diet with 20% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.

Behavioral: Diet with 20% of carb intake from soda
Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane

Experimental: Diet with 50% of carb intake from soda

This group will receive a weight-maintaining diet with 50% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.

Behavioral: Diet with 50% of carb intake from soda
Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane

Experimental: Diet with no soda

This group will receive a weight-maintaining diet without soda. All 50% of carbohydrates will originate from sources other than corn and sugar cane.

Behavioral: Diet with no soda
Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane

Outcome Measures

Primary Outcome Measures

  1. Change in the blood carbon stable isotope ratio (13C/12C) from baseline to 12 weeks. [Baseline, Week 8, Week 10, Week 12]

    We will test biomarker diet relationships at the week 8, 10 and 12 sampling time points, using linear mixed effects models to evaluate single CIR biomarkers of SSB in plasma. Specifically, we will also test the time x group interaction by including it as a fixed effect in the mixed model analysis to evaluate the differences in the rate of CIR change over time across groups. Baseline CIR will be included as covariate in the mixed model analysis.

  2. Change in the hair carbon stable isotope ratio (13C/12C) from baseline to 12 weeks. [Baseline, Week 12]

    We will test biomarker diet relationships at baseline and 12 weeks to determine differences in values over time and dose.

Secondary Outcome Measures

  1. Change in the carbon stable isotope ratio of alanine from baseline to 12 weeks. [Baseline, every two weeks through Week 12]

    We will examine the time response of CIR-alanine. We will use a difference of 1.5 (Infinite) (+/-) from baseline as a preliminary criterion and adjust to ensure balanced representation of treatments in the 'time response' subset of participants. From these participants we will measure CIR-alanine at all timepoints. We will assess temporal change in CIR- alanine by examining week-to-week correlations to identify the time point at which biomarker measurements become independent of baseline, and by using linear mixed models to model the longitudinal trends over time.

  2. Change in urinary sucrose/fructose over time and with varying levels of SSB intake. [Baseline, every two weeks through Week 12]

    Repeated measures two-way ANOVA will be employed to assess the between-subjects effect and to compare the daily sugars excretion during different levels of sugars intake.

  3. 24h EE and its components from the metabolic chamber. [Baseline, Week 1, Week 12]

    Diet-induced changes in EE will be assessed for significance using a paired t test (before/after intervention) and ANCOVA (dose).

  4. To determine the effect of dietary changes on the microbiome of the gut, single stool samples will be collected upon admission and completion. [Baseline, Week 12]

    We will measure 16s rRNA on stool samples before and after dietary intervention.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Body mass index less than or equal to 35 kg/m(2) to minimize the impact of body size on isotope measurements.

  • Women and men between the ages of 18-65 years will be recruited for this study

  • Healthy, as determined by medical history, physical examination, and laboratory tests.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Fasting plasma glucose greater than or equal to 126 mg/dL

  • Alopecia totalis or inability to grow hair (at least one inch of hair required to obtain sample)

  • Use of medication affecting metabolism and appetite in the last three months

  • Medically- or self-imposed dietary restrictions that would limit a participant s ability/willingness to consume the diet to which they are randomized

  • Current pregnancy, pregnancy within the past 6 months or currently lactating

  • History or clinical manifestations of acute or chronic disorders or conditions that may affect appetite or EE, (such as, but not limited to type 1 or type 2 diabetes, Cushing s disease, thyroid disorders, coccidiomycoses)

  • Gastrointestinal disease, including inflammatory bowel diseases (e.g. Chron s disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active) which may alter metabolism or absorption of study food

  • Current, unstable medical conditions such as hepatitis, renal insufficiency, cancer requiring treatment in the last 5 years (except for nonmelanoma skin cancers or cancers that have clearly been cured), or central nervous system disorders etc. as assessed by history and physical exam

  • Diagnosis of binge eating disorder, anorexia-nervosa, or bulimia-nervosa

  • Evidence of alcohol abuse as defined by greater than or equal to 8-point score on the Alcohol consumption screening AUDIT questionnaire in adults

  • Evidence of nicotine use or of drug use such as amphetamines, cocaine, heroin, or marijuana

  • Any condition not specifically mentioned above that, in the opinion of the investigator, may interfere with the study or prove unsafe for participation.

  • Weight change of plus or less 5% in the last 3 months, per self report.

  • Non-English speaking

  • Ability of participant to understand and the willingness to sign a written informed consent document.

Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators. Additionally, potential subjects might be excluded if they demonstrate a style of interpersonal relationships that would inhibit successful completion of the study.

Non-English-speaking subjects as a population will be excluded from participation in this protocol. One of the secondary hypotheses of the protocol relates to a battery of psychological questionnaires and performances tests which are administered to the volunteers at the beginning and end of the study. There are currently no validated, translated forms of these questionnaires and tests available; therefore, we will restrict enrollment to English speaking subjects only.

INCLUSION OF VULNERABLE PARTICIPANTS:

This study will not include vulnerable participants.

Participation of NIH Staff or family members of study team members:

NIH staff and family members of study team members may be enrolled in this study as this population meets the study entry criteria. Neither participation nor refusal to participate as a subject in the research will have an effect, either beneficial or adverse, on the participant s employment or position at NIH.

Every effort will be made to protect participant information, but such information may be available in medical records and may be available to authorized users outside of the study team in both an identifiable an unidentifiable manner.

The NIH Information Sheet on NIH Staff Research Participation will be made available.

INCLUSION OF PREGNANT WOMEN, FETUSES OR NEONATES:

N/A

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1NIDDK, PhoenixPhoenixArizonaUnited States85014

Sponsors and Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Investigators

  • Principal Investigator: Susanne Votruba, Ph.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT04799301
Other Study ID Numbers:
  • 10000043
  • 000043-DK
First Posted:
Mar 16, 2021
Last Update Posted:
Dec 3, 2021
Last Verified:
Oct 19, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Results

No Results Posted as of Dec 3, 2021